字号·· | 护眼
彭博社

拜耳中风药阿孙德西安获美国批准,有望成为重磅药物Bayer Wins US Approval for Potential Blockbuster Stroke Drug

点「原文对照」整页切到原文,或双击某段只看那段的原文。

拜耳公司(AG)的中风药物阿孙德西安赢得美国批准,为其制药业务部门提供了助力,而该部门一些最大的药物正面临仿制药竞争。

AG won US approval for stroke drug asundexian, bolstering the German company’s pharmaceutical unit as some of its biggest medicines face generic competition.

美国食品药品监督管理局在其网站上表示,已批准阿孙德西安用于预防已经发生过一次中风的人再次中风。

The Food and Drug Administration approved asundexian to prevent additional strokes in people who already have suffered one, the agency said on its website.

此次批准基于一项临床研究的积极结果:研究显示,在抗血小板治疗的基础上加用该疗法,可使二次中风风险降低26%,且未增加严重出血。相关阅读:拜耳的阿孙德西安药物在研究中使中风风险降低26%拜耳的口服疗法通过阻断一种名为凝血因子XIa的蛋白质发挥作用,这种蛋白质参与血液凝固。阿孙德西安是该类药物中首个获批的药物,也已于10月底在中国获批。竞争对手百时美施贵宝公司和强生公司正在测试一种类似药物米尔维西安。

The approval follows positive results in a clinical study that showed the therapy reduced the risk of secondary strokes by 26% when added to antiplatelet therapy, without increasing serious bleeding. Read: Bayer’s Asundexian Drug Reduces Stroke Risk by 26% in Study Bayer’s oral treatment works by blocking a protein called Factor XIa, which plays a role in blood clotting. Asundexian is the first approved drug of this class and was also approved in China in late October. Rivals Bristol Myers Squibb Co. and Johnson & Johnson are testing a similar drug called milvexian.

该药物预计将帮助拜耳推动其制药业务部门的增长,该部门正艰难应对抗凝药拜瑞妥和眼科药物艾力雅的仿制药竞争。公司较新的药物包括更年期药物Lynkuet和心脏治疗药物Beyonttra。

The medicine is expected to help Bayer drive growth in its pharma unit, which is grappling with generic competition to blood-thinner Xarelto and eye medicine Eylea. The company’s newer drugs include the menopause medicine Lynkuet and heart treatment Beyonttra.

制药业务部门负责人斯特凡·奥利希此前表示,该药物具有成为重磅中风治疗药物的潜力。它此前作为一种心脏疾病的疗法未能成功。

The head of the pharma unit, Stefan Oelrich, previously said the drug — which earlier failed as a therapy for a heart condition — has blockbuster potential as a stroke treatment.

阿孙德西安全球负责人扬·福斯在接受采访时表示,销售机会的大小还将取决于该药物即将进行的价格谈判。他强调,该药物是约二十年来二次中风预防领域的首个创新。

The size of the sales opportunity will also depend on upcoming price negotiations for the drug, Jan Voss, global head for asundexian, said in an interview. He stressed that the drug represents the first innovation in secondary stroke prevention in about two decades.

“我们非常有信心,这将成为拜耳未来重要的增长动力,而且是可持续的,”福斯说,并补充称该专利延伸“至2030年代后期”。公司今年在与其“农达”除草剂相关的美国诉讼方面也传来利好消息。6月,公司获得美国最高法院的有利裁决,目前正等待另一法院对其72.5亿美元和解提议作出裁决。首席执行官比尔·安德森承诺,到2026年底将大幅遏制法律麻烦。

“We are very confident that this will be an important future growth driver for Bayer, and one that is also sustainable,” Voss said, adding that the patent extends “well into the 2030s.”The company also had positive news this year on the US litigation tied to its Roundup weedkiller. It received a favorable US Supreme Court decision in June and is awaiting a separate court’s ruling for its $7.25 billion settlement proposal. Chief Executive Officer Bill Anderson has pledged to significantly contain the legal troubles by the end of 2026.

阅读媒体原文 ↗